- Stocks
- Pharma & Healthcare
- Procter Gamble
Procter Gamble share price
NSE: PGHHPharma & HealthcareHousehold & Personal Products
Procter Gamble at a glance
Procter Gamble (NSE: PGHH) closed at ₹6,856.00 on 22 Oct 2026, down 0.36% on the day. With a market capitalisation of ₹22,255 Cr, it ranks 331st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Household & Personal Products.
At its last close the stock traded at 26× trailing earnings, against a return on equity of 62.3% in FY26. Over the past year the share price has fallen 51.5%. Its 52-week range is ₹6,579.00 (1 Oct 2026) to ₹13,903.00 (23 Oct 2025); the last close is 50.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹890 Cr (−4.8% year on year) and net profit ₹126 Cr (−34.3%), on a standalone basis. Promoters held 70.64% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹22,255 CrRank 331 on NSE
- P/E (trailing)
- 26×
- Price to book
- 15.18×FY26
- EPS (TTM)
- ₹243.59to Q1 FY27
- ROE
- 62.3%FY26
- ROCE
- 76.8%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 23.2%FY26
- Book value / share
- ₹315.99FY26
- 52-week high
- ₹13,903.0023 Oct 2025
- 52-week low
- ₹6,579.001 Oct 2026
- 1-year return
- −51.5%
- RSI (14-day)
- 36.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.36% | −3.8% | −7.5% | −23.8% | −51.5% |
Procter Gamble quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,135 Cr | ₹1,246 Cr | ₹989 Cr | ₹935 Cr | ₹1,149 Cr | ₹1,260 Cr | ₹941 Cr | ₹890 Cr |
| Revenue YoY | +0.0% | +10.2% | −1.3% | +0.4% | +1.2% | +1.1% | −4.8% | −4.8% |
| Net profit | ₹212 Cr | ₹269 Cr | ₹156 Cr | ₹192 Cr | ₹210 Cr | ₹301 Cr | ₹153 Cr | ₹126 Cr |
| Net profit YoY | +0.6% | +17.3% | +1.1% | +136.9% | −1.0% | +12.2% | −1.9% | −34.3% |
| Net margin | 18.7% | 21.6% | 15.8% | 20.5% | 18.3% | 23.9% | 16.3% | 14.2% |
| EPS | ₹65.28 | ₹82.74 | ₹48.09 | ₹59.17 | ₹64.65 | ₹92.87 | ₹47.17 | ₹38.90 |
Procter Gamble financials
| Item | FY22 | FY23 | FY24 | FY25 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,009 Cr | ₹1,114 Cr | ₹1,230 Cr | ₹1,151 Cr | ₹934 Cr | — |
| Operating profit | ₹233 Cr | ₹253 Cr | ₹314 Cr | ₹294 Cr | ₹312 Cr | — |
| Net profit | ₹177 Cr | ₹193 Cr | ₹229 Cr | ₹201 Cr | ₹234 Cr | — |
| EPS (₹) | ₹107.00 | ₹116.00 | ₹138.00 | ₹133.00 | ₹141.00 | — |
| Cash from operations | ₹247 Cr | ₹170 Cr | ₹236 Cr | ₹228 Cr | ₹169 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹704 Cr | ₹616 Cr | ₹751 Cr | ₹538 Cr | ₹537 Cr | ₹525 Cr |
Procter Gamble shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% |
| Foreign institutions | 1.33% | 1.38% | 1.11% | 1.07% | 0.97% | 0.98% |
| Domestic institutions | 15.51% | 15.49% | 16.06% | 16.04% | 15.97% | 15.59% |
| Non-institutions | 12.52% | 12.48% | 12.19% | 12.26% | 12.43% | 12.80% |
Procter Gamble vs peers
The listed Pharma & Healthcare companies nearest to Procter Gamble by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NEULANDLABNeuland Laboratories | ₹18,855.00 | −0.45% | +16.3% | ₹24,191 Cr | 66.3 | — |
| RUBICONRubicon Research | ₹1,408.90 | −3.57% | — | ₹23,301 Cr | 92.3 | — |
| PGHHProcter Gamble | ₹6,856.00 | −0.36% | −51.5% | ₹22,255 Cr | 26 | — |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹44.78 | +1.08% | +0.9% | ₹20,963 Cr | 22.6 | — |
| GRANULESGranules India | ₹807.65 | +0.04% | +41.9% | ₹20,013 Cr | 33 | — |
| IGLIndraprastha | ₹141.87 | −0.11% | −33.1% | ₹19,862 Cr | 12.8 | — |
Ask anything about Procter Gamble
Pivot answers on the live chart with evidence you can check, and tests strategies against PGHH's own history. Try: “Why has PGHH moved over the last three months?” · “Backtest a 50-day moving-average crossover on PGHH over five years” · “Compare PGHH with NEULANDLAB on margins and valuation”
Frequently asked questions about Procter Gamble
What is the share price of Procter Gamble today?
Procter Gamble (NSE: PGHH) last closed at ₹6,856.00 on 22 Oct 2026. Its 52-week high is ₹13,903.00 and its 52-week low is ₹6,579.00.
What is the market cap of Procter Gamble?
Procter Gamble's market capitalisation is ₹22,255 Cr (₹22,255 Cr) at the 22 Oct 2026 close, ranking 331st among the NSE companies Pivot tracks.
What is the P/E ratio of Procter Gamble?
Procter Gamble trades at a trailing P/E of 26. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 33.
What is the ROE and ROCE of Procter Gamble?
Return on equity was 62.3% in FY26 and return on capital employed was 76.8% in FY26 (standalone figures).
Is Procter Gamble a debt-free company?
Procter Gamble is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Procter Gamble's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Procter Gamble reported revenue of ₹890 Cr, −4.8% year on year, and net profit of ₹126 Cr, −34.3% year on year.
How has Procter Gamble stock performed over the last year?
Procter Gamble's share price has fallen 51.5% over the past year, −23.8% over three months and −7.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Procter Gamble?
As of 30 Jun 2026: promoters 70.64%, foreign institutions 0.98%, domestic institutions 15.59%, non-institutions 12.80%.
Who are Procter Gamble's competitors?
The listed Pharma & Healthcare companies closest to Procter Gamble by market cap are Neuland Laboratories, Rubicon Research, Piramal Phytoca, SAGILITY, Granules India and Indraprastha.
Is Procter Gamble a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Procter Gamble's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PGHH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text